...
agio-img

Agios Pharm, Common Stock

AGIO

NSQ

$35.42

-$0.39

(-1.09%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$2.23B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
3.3465
Volume info-icon
This is the total number of shares traded during the most recent trading day.
1.57M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.75
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$20.96 L
$62.58 H
$35.42

About Agios Pharm, Common Stock

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameAGIOSectorS&P500
1-Week Return-9.1%-2.12%-3%
1-Month Return-35.15%-3.42%-0.73%
3-Month Return-23.91%-11.13%2.87%
6-Month Return-16.56%-5.74%7.17%
1-Year Return53.6%3.97%25.31%
3-Year Return4.7%1.05%28.38%
5-Year Return-27.1%34.37%81.89%
10-Year Return-70.67%97.88%183.27%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue117.91M203.20M41.41K14.24M26.82M[{"date":"2019-12-31","value":58.03,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":0.02,"profit":true},{"date":"2022-12-31","value":7.01,"profit":true},{"date":"2023-12-31","value":13.2,"profit":true}]
Cost of Revenue1.32M2.81M18.78M1.70M9.50M[{"date":"2019-12-31","value":7.01,"profit":true},{"date":"2020-12-31","value":14.94,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":9.07,"profit":true},{"date":"2023-12-31","value":50.62,"profit":true}]
Gross Profit116.59M200.39M(18.78M)12.54M17.32M[{"date":"2019-12-31","value":58.18,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-9.37,"profit":false},{"date":"2022-12-31","value":6.26,"profit":true},{"date":"2023-12-31","value":8.64,"profit":true}]
Gross Margin98.88%98.62%(45345.21%)88.03%64.57%[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":99.73,"profit":true},{"date":"2021-12-31","value":-45857.41,"profit":false},{"date":"2022-12-31","value":89.03,"profit":true},{"date":"2023-12-31","value":65.3,"profit":true}]
Operating Expenses542.93M516.54M378.42M401.58M408.81M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":95.14,"profit":true},{"date":"2021-12-31","value":69.7,"profit":true},{"date":"2022-12-31","value":73.97,"profit":true},{"date":"2023-12-31","value":75.3,"profit":true}]
Operating Income(426.33M)(316.15M)(378.42M)(389.05M)(391.49M)[{"date":"2019-12-31","value":-42633300000,"profit":false},{"date":"2020-12-31","value":-31614900000,"profit":false},{"date":"2021-12-31","value":-37841800000,"profit":false},{"date":"2022-12-31","value":-38904700000,"profit":false},{"date":"2023-12-31","value":-39148700000,"profit":false}]
Total Non-Operating Income/Expense29.72M(4.61M)22.74M170.04M72.74M[{"date":"2019-12-31","value":17.48,"profit":true},{"date":"2020-12-31","value":-2.71,"profit":false},{"date":"2021-12-31","value":13.38,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":42.78,"profit":true}]
Pre-Tax Income(411.47M)(327.37M)(356.51M)(231.80M)(352.09M)[{"date":"2019-12-31","value":-41147200000,"profit":false},{"date":"2020-12-31","value":-32737000000,"profit":false},{"date":"2021-12-31","value":-35651000000,"profit":false},{"date":"2022-12-31","value":-23180100000,"profit":false},{"date":"2023-12-31","value":-35208800000,"profit":false}]
Income Taxes(14.86M)7.85M(1.98B)(157.25M)6.46M[{"date":"2019-12-31","value":-189.36,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-25203.11,"profit":false},{"date":"2022-12-31","value":-2003.64,"profit":false},{"date":"2023-12-31","value":82.25,"profit":true}]
Income After Taxes(396.61M)(335.22M)1.62B(74.56M)(358.54M)[{"date":"2019-12-31","value":-24.46,"profit":false},{"date":"2020-12-31","value":-20.67,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-4.6,"profit":false},{"date":"2023-12-31","value":-22.11,"profit":false}]
Income From Continuous Operations(411.47M)(309.54M)(356.51M)(231.80M)(352.09M)[{"date":"2019-12-31","value":-41147200000,"profit":false},{"date":"2020-12-31","value":-30953800000,"profit":false},{"date":"2021-12-31","value":-35651000000,"profit":false},{"date":"2022-12-31","value":-23180100000,"profit":false},{"date":"2023-12-31","value":-35208800000,"profit":false}]
Income From Discontinued Operations1.96B1.96B1.96B--[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(396.61M)(335.22M)1.60B(74.56M)(352.09M)[{"date":"2019-12-31","value":-24.72,"profit":false},{"date":"2020-12-31","value":-20.89,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-4.65,"profit":false},{"date":"2023-12-31","value":-21.94,"profit":false}]
EPS (Diluted)(6.87)(4.74)22.21(4.24)(6.34)[{"date":"2019-12-31","value":-30.93,"profit":false},{"date":"2020-12-31","value":-21.34,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-19.09,"profit":false},{"date":"2023-12-31","value":-28.55,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

AGIO
Cash Ratio 8.41
Current Ratio 8.99
Quick Ratio 8.77

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

AGIO
ROA (LTM) -18.18%
ROE (LTM) 53.66%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

AGIO
Debt Ratio Lower is generally better. Negative is bad. 0.09
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.91

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

AGIO
Trailing PE 3.07
Forward PE 2.47
P/S (TTM) 62.13
P/B 1.37
Price/FCF NM
EV/R 38.98
EV/Ebitda NM
PEG NM

FAQs

What is Agios Pharm share price today?

Agios Pharm (AGIO) share price today is $35.42

Can Indians buy Agios Pharm shares?

Yes, Indians can buy shares of Agios Pharm (AGIO) on Vested. To buy Agios Pharm from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in AGIO stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Agios Pharm be purchased?

Yes, you can purchase fractional shares of Agios Pharm (AGIO) via the Vested app. You can start investing in Agios Pharm (AGIO) with a minimum investment of $1.

How to invest in Agios Pharm shares from India?

You can invest in shares of Agios Pharm (AGIO) via Vested in three simple steps:

  • Click on Sign Up or Invest in AGIO stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Agios Pharm shares
What is Agios Pharm 52-week high and low stock price?

The 52-week high price of Agios Pharm (AGIO) is $62.58. The 52-week low price of Agios Pharm (AGIO) is $20.96.

What is Agios Pharm price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Agios Pharm (AGIO) is 3.3465

What is Agios Pharm price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Agios Pharm (AGIO) is 1.37

What is Agios Pharm dividend yield?

The dividend yield of Agios Pharm (AGIO) is 0.00%

What is the Market Cap of Agios Pharm?

The market capitalization of Agios Pharm (AGIO) is $2.23B

What is Agios Pharm’s stock symbol?

The stock symbol (or ticker) of Agios Pharm is AGIO

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top